Plain-English translation of NCT06329999 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new combination treatment for adults with a type of blood cancer called acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned after previous treatment or didn't respond to it. The combination includes Mitoxantrone Liposomes (a cancer-fighting drug delivered in a special form), along with three other medications designed to work together. The goal is to see if this medication combination can help patients whose cancer has been difficult to treat.
Previous studies have shown that this combination works well in similar patients, but the original form of one of the drugs hasn't been available for treatment in some areas for a long time. This new liposomal form is designed to be safer and more effective, and researchers want to confirm it works for people with hard-to-treat blood cancers.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the four-drug medication combination as part of your cancer treatment. You would need to attend visits at the hospital or clinic where your doctors monitor how well the treatment is working and check for any side effects through blood tests and heart monitoring. The trial involves 78 patients total across multiple centers, and your doctors will work with you to manage any side effects while evaluating whether the treatment is helping your cancer.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China